Trial Profile

A phase I study evaluating BHV-1300

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BHV-1300 (Primary)
Indications Graves' disease; Immunological disorders; Rheumatoid arthritis
Focus First in man; Therapeutic Use

Most Recent Events

28 May 2025 Results presented in a Biohaven Media Release.
03 Mar 2025 According to Biohaven media release, the company announced that BHV-1300 Phase 1 with the optimized subcutaneous formulation completing in 1H 2025.
12 Nov 2024 According to Biohaven media release, company plans to share further study update in 4Q 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com